IpsenIPSEF 95 Pretax Margin % is 7.68% as of Dec. 2025, which is 60% below its 10-year median of 19.13. GuruFocus rates IPSEF with a GF Score™ of 95/100 and a GF Value™ of $92.81. The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, Ipsen ranks better than 69.74% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Ipsen's Pre-Tax Income for the
six
months ended in Dec. 2025 was $179 Mil. Ipsen's Revenue for the
six
months ended in Dec. 2025 was $2,333 Mil. Therefore, Ipsen's pretax margin for the quarter that ended in Dec. 2025 was 7.68%.
The historical rank and industry rank for Ipsen's Pretax Margin % or its related term are showing as below:
IPSEF'
s Pretax Margin % Range Over the Past 10 Years
Min: -1.44 Med: 19.13 Max: 28.71
Current: 14.73
IPSEF's Pretax Margin % is ranked better than 69.74% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs IPSEF: 14.73
Ipsen (OTCPK:IPSEF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Ipsen Pretax Margin % Related Terms
Ipsen Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Ipsen's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPSEF vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ipsen Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ipsen's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Ipsen's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ipsen (IPSEF) has a Pretax Margin % of 7.68% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Ipsen and its competitors. This is 60% below median its historical median of 19.13. According to the industry distribution chart, Ipsen ranks #289 out of 955 companies in the Drug Manufacturers industry, placing it in the top 30.3%.
Is Ipsen's Pretax Margin % too high?
Ipsen's current Pretax Margin % of 7.68% is 60% below median its 10-year median of 19.13. The Drug Manufacturers industry median Pretax Margin % is 7.28. Ipsen's value of 7.68% is 5.5% above this industry median. Based on the distribution chart, Ipsen ranks #289 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ipsen has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Ipsen's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ipsen ranks #289 out of 955 companies for Pretax Margin %. This puts Ipsen in the upper half of its industry. The industry median Pretax Margin % is 7.28. Ipsen's value of 7.68% is 5.5% above this benchmark. While the company's 10-year median is 19.13 vs. the industry median of 7.28, Ipsen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ipsen's current Pretax Margin % of 7.68% is 5.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Ipsen and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ipsen's current Pretax Margin % is 7.68%, which is 60% below median its own 10-year median of 19.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipsen stock overvalued right now?
Ipsen (IPSEF) has a current Pretax Margin % of 7.68%. The stock's GF Value™ is $92.81, compared to a current price of $113.13 — trading 21.9% above its estimated fair value. The current Pretax Margin % is 7.68%, which is 60% below median its 10-year median of 19.13 and 5.5% above the Drug Manufacturers industry median of 7.28. Ipsen's overall GF Score™ is 95/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Ipsen (IPSEF), the current Pretax Margin % is 7.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ipsen (IPSEF) Overvalued in 2026?
Based on GuruFocus' analysis, Ipsen stock appears to be overvalued.
The current stock price of $113.13 is trading 21.9% above its estimated GF Value™ of $92.81.
Key valuation signals for IPSEF:
Pretax Margin %: 7.68% (60% below median its 10-year median of 19.13)
GF Value™: $92.81 vs. price of $113.13 (21.9% above fair value)
Industry Position: 5.5% above the Drug Manufacturers median (#289 of 955)
No single metric tells the full story. See the IPSEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
95GF Score
Get the complete analysis for IPSEF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPSEF has been successfully added to your 
